Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

Four Janus kinases (JAKs) (JAK1, JAK2, JAK3, TYK2) and seven signal transducers and activators of transcription (STATs) (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6) mediate the signal transduction of more than 50 cytokines and growth factors in many different cell types. Located intracellularly and downstream of cytokine receptors, JAKs integrate and balance the actions of various signaling pathways. With distinct panels of STAT-sensitive genes in different tissues, this highly heterogeneous system has broad in vivo functions playing a crucial role in the immune system. Thus, the JAK/STAT pathway is critical for resisting infection, maintaining immune tolerance, and enforcing barrier functions and immune surveillance against cancer. Breakdowns of this system and/or increased signal transduction may lead to autoimmunity and other diseases. Accordingly, the recent development and approval of the first small synthetic molecules targeting JAK molecules have opened new therapeutic avenues of potentially broad therapeutic relevance. Extensive data are now available regarding the JAK/STAT pathway in rheumatoid arthritis. Dysregulation of the cytokines is also a hallmark of systemic lupus erythematosus (SLE), and targeting the JAK/STAT proteins allows simultaneous suppression of multiple cytokines. Evidence from in vitro studies and animal models supports a pivotal role also in the pathogenesis of cutaneous lupus and SLE. This has important therapeutic implications, given the current paucity of targeted therapies especially in the latter. Herein, we summarize the currently available literature in experimental SLE, which has led to the recent promising Phase II clinical trial of a JAK inhibitor.

• Publication year

  2019

• Venue

  Cells

• Publication date

  2019-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/cells8080898PMID 31443172PMCID 6721755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WNT Signaling in Hematological Malignancies

  2020cited by this paper
• Clinical efficacy of new JAK inhibitors under development. Just more of the same?

  2019cited by this paper
• Baricitinib for systemic lupus erythematosus.

  2019cited by this paper
• The regulation of JAKs in cytokine signaling and its breakdown in disease.

  2019cited by this paper
• 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

  2019cited by this paper
• Novel paradigms in systemic lupus erythematosus.

  2019cited by this paper
• Lupus community panel proposals for optimising clinical trials: 2018

  2018cited by this paper
• The Jakinibs in systemic lupus erythematosus: progress and prospects

  2018cited by this paper
• The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE

  2018influential reference
• Baricitinib for systemic lupus erythematosus.

  2018cited by this paper
• S3I-201 ameliorates tubulointerstitial lesion of the kidneys in MRL/lpr mice.

  2018cited by this paper
• Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

  2018cited by this paper
• Systemic lupus erythematosus: state of the art on clinical practice guidelines

  2018cited by this paper
• JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation

  2017cited by this paper
• Mechanisms and consequences of Jak–STAT signaling in the immune system

  2017cited by this paper
• An update on lupus animal models

  2017cited by this paper
• A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro

  2017cited by this paper
• Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

  2017cited by this paper
• Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

  2017influential reference
• JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

  2017cited by this paper
• JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus

  2017cited by this paper
• Clinical relevance of circulating anti‐ENA and anti‐dsDNA secreting cells from SLE patients and their dependence on STAT‐3 activation

  2017cited by this paper
• JAK3-STAT pathway blocking benefits in experimental lupus nephritis

  2016influential reference
• Therapeutic Potential for Targeting the Suppressor of Cytokine Signalling‐1 Pathway for the Treatment of SLE

  2016cited by this paper
• JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.

  2016cited by this paper
• STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus

  2016cited by this paper
• Prion‐like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon

  2016cited by this paper
• The JAK-STAT pathway: impact on human disease and therapeutic intervention.

  2015cited by this paper
• Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.

  2015cited by this paper
• The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

  2015cited by this paper
• Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model.

  2015cited by this paper
• VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease

  2015influential reference
• Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice.

  2015cited by this paper
• Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

  2015cited by this paper
• Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.

  2015cited by this paper
• SOCS signaling in autoimmune diseases: Molecular mechanisms and therapeutic implications

  2014cited by this paper
• Prevention of Murine Lupus Nephritis by Targeting Multiple Signaling Axes and Oxidative Stress Using a Synthetic Triterpenoid

  2014cited by this paper
• Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome.

  2013cited by this paper
• Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

  2013influential reference
• JAK/STAT signaling in hematological malignancies

  2013cited by this paper
• JAK2 inhibition in murine systemic lupus erythematosus.

  2012cited by this paper
• The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

  2012cited by this paper
• Comparative evolutionary genomics of the STAT family of transcription factors

  2012cited by this paper
• Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

  2011influential reference
• Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus

  2011cited by this paper
• A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).

  2010cited by this paper
• Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

  2010influential reference
• Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice

  2010influential reference
• Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis.

  2008cited by this paper
• Paradigm shifts in the cell biology of STAT signaling.

  2008cited by this paper
• Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB.

  2007cited by this paper
• STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.

  2007cited by this paper
• Activation of the signal transducer and activator of transcription-1 in diffuse proliferative lupus nephritis

  2007cited by this paper
• Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice

  2007cited by this paper
• STAT3 mutations in the hyper-IgE syndrome.

  2007cited by this paper
• The Jak1 SH2 Domain Does Not Fulfill a Classical SH2 Function in Jak/STAT Signaling but Plays a Structural Role for Receptor Interaction and Up-regulation of Receptor Surface Expression*

  2005cited by this paper
• Real Time Analysis of STAT3 Nucleocytoplasmic Shuttling*

  2004cited by this paper
• The Janus kinases (Jaks)

  2004cited by this paper
• Pivotal Role of Stat4 and Stat6 in the Pathogenesis of the Lupus-Like Disease in the New Zealand Mixed 2328 Mice 1

  2003cited by this paper
• Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

  2003cited by this paper
• STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study.

  2002cited by this paper
• Cellular Physiology of STAT3: Where’s the Cytoplasmic Monomer?*

  1999cited by this paper
• Jaks and STATs: biological implications.

  1998cited by this paper
• Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

  1995cited by this paper
• Nephritis.

  1938cited by this paper

• Management strategies for systemic lupus erythematosus using kinase inhibitors

  2026cites this paper
• Janus kinase inhibitors and the risk of infections: a network meta-analysis across disease indications.

  2025cites this paper
• Interleukin 15 and autoimmune disorders: pathophysiology, therapeutic potential, and clinical implications

  2025cites this paper
• Gene and RNA Editing: Revolutionary Approaches to Treating Diseases

  2025cites this paper
• Glycyrrhizin alleviates renal damage in MRL/lpr mice by modulating gut microbiota dysbiosis and regulating the RTK-PKCα axis: insights from reverse network pharmacology.

  2025cites this paper
• Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights

  2025cites this paper
• Direct reprogramming of human fibroblasts into hair-inducing dermal papilla cell-like cells by a single small molecule.

  2025cites this paper
• Comprehensive analysis of eccDNA characteristics and associated genes expression in peripheral blood of ASLE and ISLE patients

  2025cites this paper
• STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer

  2025cites this paper
• Exploring the association between rosacea and acne by integrated bioinformatics analysis

  2024cites this paper
• Genetic interrogation for sequence and copy number variants in systemic lupus erythematosus

  2024cites this paper
• Gut microbiota CLA and IL-35 induction in macrophages through Gαq/11-mediated STAT1/4 pathway: an animal-based study

  2024cites this paper
• Exploring Si-Ni-San's therapeutic dynamics in autoimmune thyroid disorders: A network pharmacology approach and experimental evidence.

  2024cites this paper
• The Molecular Signature Related to Local Inflammatory and Immune Response in Canine Cutaneous Hypersensitivity Reactions: A Preliminary Study

  2024cites this paper
• The JAK-STAT pathway: from structural biology to cytokine engineering

  2024cites this paper
• Therapeutic potential of Nelumbo nucifera Linn. in systemic lupus erythematosus: Network pharmacology and molecular modeling insights

  2024cites this paper
• Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease.

  2024cites this paper
• Epigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defense

  2024cites this paper
• JAK/STAT Signalling Overdrive in Immune Regulation: A Trigger for Autoimmunity

  2024cites this paper
• Janus Kinases and Autoimmunity: Bridging Pathways to Therapy

  2024cites this paper
• Mechanisms of Tripterygium wilfordii Hook F on treating rheumatoid arthritis explored by network pharmacology analysis and molecular docking

  2024cites this paper
• Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors.

  2024cites this paper
• Impact of Interleukin-17 Receptor A Gene Variants on Asthma Susceptibility and Clinical Manifestations in Children and Adolescents

  2024cites this paper
• Small molecule drug discovery targeting the JAK-STAT pathway.

  2024cites this paper
• Biologische Therapie bei systemischem Lupus erythematodes, Antiphospholipid-Syndrom und Sjögren-Syndrom: evidenz- und praxisbasierte Leitlinien

  2024cites this paper
• Computer-Aided Drug Design of Novel Derivatives of 2-Amino-7,9-dihydro-8H-purin-8-one as Potent Pan-Janus JAK3 Inhibitors

  2023cites this paper
• Analysis of microRNA-199a-3p expression in CD4^+ T cells of systemic lupus erythematosus

  2023cites this paper
• Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry

  2023cites this paper
• Profile of plasma free amino acids, carnitine and acylcarnitines, and JAK2v617f mutation as potential metabolic markers in children with type 1 diabetic nephropathy.

  2023cites this paper
• Erucic acid improves the progress of pregnancy complicated with systemic lupus erythematosus by inhibiting the effector function of CD8+ T cells

  2023cites this paper
• Decoding the mitochondrial connection: development and validation of biomarkers for classifying and treating systemic lupus erythematosus through bioinformatics and machine learning

  2023cites this paper
• Qijia rougan formula ameliorates ECM deposition in hepatic fibrosis by regulating the JAK1/STAT6-microRNA-23a feedback loop in macrophage M2 polarization.

  2023cites this paper
• L-Carnitine and Chronic Kidney Disease: A Comprehensive Review on Nutrition and Health Perspectives

  2023cites this paper
• JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17/Treg cells via regulating the JAK2/STAT3-AKT/mTOR signaling pathway.

  2023cites this paper
• Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report

  2023cites this paper
• A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019

  2023cites this paper
• Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Jiegeng Decoction in Improving Allergic Asthma

  2023cites this paper
• Fibrosis: Types, Effects, Markers, Mechanisms for Disease Progression, and Its Relation with Oxidative Stress, Immunity, and Inflammation

  2023cites this paper
• QSAR-driven screening uncovers and designs novel pyrimidine-4,6-diamine derivatives as potent JAK3 inhibitors

  2023cites this paper
• Integrated bioinformatics analysis identifies shared immune changes between ischemic stroke and COVID 19

  2023cites this paper
• Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway

  2023cites this paper
• Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus

  2023cites this paper
• A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma.

  2023cites this paper
• Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: evidence- and practice-based guidance

  2023cites this paper
• Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

  2023cites this paper
• Recent progress on tyrosine kinase 2 JH2 inhibitors.

  2023cites this paper
• Effects of Dietary Oleacein Treatment on Endothelial Dysfunction and Lupus Nephritis in Balb/C Pristane-Induced Mice

  2023cites this paper
• Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition

  2023cites this paper
• Advances in the research of plant-derived natural products against retinoblastoma.

  2022cites this paper
• B cell-targeted therapies in systemic lupus erythematosus.

  2022cites this paper
• A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal

  2022cites this paper
• Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy

  2022cites this paper
• Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

  2022cites this paper
• Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus.

  2022cites this paper
• Serum extracellular traps associate with the activation of myeloid cells in SLE patients with the low level of anti-DNA antibodies

  2022cites this paper
• Quantification of an Anti-Rheumatic Agent: Upadacitinib in Biological Fluid (Plasma) By LC- MS/MS

  2022cites this paper
• Combined proteomics and single cell RNA-sequencing analysis to identify biomarkers of disease diagnosis and disease exacerbation for systemic lupus erythematosus

  2022cites this paper
• Applications and Mechanisms of Tripterygium Wilfordii Hook. F. and its Preparations in Kidney Diseases

  2022cites this paper
• JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies

  2022cites this paper
• Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs

  2022cites this paper
• Successful remission with tofacitinib in a patient with refractory bullous systemic lupus erythematosus.

  2022cites this paper
• ICAM-1 targeted thermal-sensitive micelles loaded with tofacitinib for enhanced treatment of rheumatoid arthritis via microwave assistance.

  2022cites this paper
• Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease

  2022cites this paper
• The Impact of STAT3 rs1053005 Variation on Type 1 Diabetes Mellitus Susceptibility: Association Study and in Silico Analysis

  2022cites this paper
• Involvement of MST1/mTORC1/STAT1 activity in the regulation of B‐cell receptor signalling by chemokine receptor 2

  2022cites this paper
• The anti-inflammatory effects of Hedyotis diffusa Willd on SLE with STAT3 as a key target.

  2022cites this paper
• Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors

  2021cites this paper
• Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

  2021cites this paper
• Molecular mechanism of the anti-inflammatory effects of Sophorae Flavescentis Aiton identified by network pharmacology

  2021cites this paper
• JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis

  2021cites this paper
• A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.

  2021cites this paper
• Emerging roles of circular RNAs in systemic lupus erythematosus

  2021cites this paper
• Baricitinib: From Rheumatoid Arthritis to COVID‐19

  2021cites this paper
• JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes.

  2021cites this paper
• Molecular Functions of WWOX Potentially Involved in Cancer Development

  2021cites this paper
• Coronavirus disease 2019 (COVID-19) and autoimmunity

  2021cites this paper
• Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management

  2021cites this paper
• The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan

  2021cites this paper
• Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

  2021cites this paper
• Five years follow-up of Juvenile lupus nephritis: a single-center retrospective cohort study.

  2021cites this paper
• Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.

  2021cites this paper
• Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?

  2021cites this paper
• Insights into COVID-19 Chemotherapies: Potential and Challenges

  2021cites this paper
• Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus

  2021cites this paper
• MiR-146b-5p targets IFI35 to inhibit inflammatory response and apoptosis via JAK1/STAT1 signalling in lipopolysaccharide-induced glomerular cells

  2021cites this paper
• Hydralazine attenuates renal inflammation in diabetic rats with ischemia/reperfusion acute kidney injury.

  2021cites this paper
• Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

  2021cites this paper
• A systematic review on nephron protective AYUSH drugs as constituents of NEERI-KFT (A traditional Indian polyherbal formulation) for the management of chronic kidney disease

  2021cites this paper
• Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

  2021cites this paper
• Investigating binding potential of carotenoid pathway bioactive molecules for ACE2 receptor of SARS-CoV-2: Possibility of a saffron based remedy for novel coronavirus!

  2021cites this paper
• SARS CoV-2 structure, biology, immunology and clinical course: exploring the value of traditional medicine in limiting COVID-19 individual risk and disease outcomes

  2021cites this paper
• CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice

  2021cites this paper
• Aberrant DNA methylation of the promoters of JAK2 and SOCS3 in juvenile systemic lupus erythematosus

  2021cites this paper
• Update on treatment strategies for vasculitis affecting the central nervous system.

  2021cites this paper
• Chitooligosaccharides alleviate hepatic fibrosis by regulating the polarization of M1 and M2 macrophages.

  2021cites this paper
• Mesangial Cells in Lupus Nephritis

  2021cites this paper
• Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

  2021cites this paper
• Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

  2021cites this paper
• Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.

  2020cites this paper
• COVID-19 bei Kindern und Jugendlichen

  2020cites this paper